6533b7d5fe1ef96bd1264530

RESEARCH PRODUCT

Change of COPD maintenance medication over two years in a large real life cohort: The DACCORD study

Roland BuhlN LossiPeter KardosClaudia MailaenderCarl-peter CriéeClaus VogelmeierHeinrich Worth

subject

Pediatricsmedicine.medical_specialtyCOPDbiologybusiness.industryMean ageLamabiology.organism_classificationmedicine.diseaseDual bronchodilationCohortmedicineCopd assessment testObservational studybusinessBaseline (configuration management)

description

Introduction Database studies suggest a steady intensification of COPD maintenance medication, with the majority of patients eventually receiving a LABA/LAMA/ICS combination. However, such studies include generally only data on medication use. Here, we analysed data from the ongoing, non-interventional, observational DACCORD study to determine whether there was a correlation between baseline GOLD 2011 category and change in medication use over 2 years. Methods This abstract presents data on medication use at baseline and at 1 and 2 years, by baseline GOLD 2011 category (A,B,C and D with symptoms evaluated using the COPD Assessment Test). Results 3315 patients with COPD have completed the 2 year follow-up (58.6% male, mean age 65.6 years) in 349 centres. The changes from baseline to Year 1, and from Year 1 to Year 2 in maintenance COPD medication use, by baseline GOLD 2011 category, are shown in Table 1. Conclusions Over the 2-year study period, there was a shift from monotherapy to dual bronchodilation (LABA/LAMA), but no important change in the proportion of patients on ICS-containing dual or triple regimens. The majority of shifts occurred in the first year. Baseline GOLD 2011 category did not appear to correlate with any shifts observed.

https://doi.org/10.1183/13993003.congress-2016.pa550